Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05944237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HTL0039732 in Participants With Advanced Solid Tumours

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 6 months later Jun 2027 → Dec 31, 2028
See other at-risk trials from Cancer Research UK

Record History

  1. Primary and study completion pushed from Jun 2027 to Dec 31, 2028 Interventions modified · Study sites: 5 to 6 · Start date: Jul 13, 2023 to Aug 2, 2023 · 4 more Show 7 more changesShow less
    • Interventions modified
    • Study sites: 5 to 6
    • Start date: Jul 13, 2023 to Aug 2, 2023
    • Eligibility criteria expanded, about 140 words
    • Secondary endpoints revised (18)
    • Study description expanded, about 7 words
    • Publications: details revised at 1 of 1 entry
  2. Primary and study completion dates: Sep 2026 to Jun 2027 Primary endpoints revised (4) · Eligibility criteria expanded, about 228 words · Secondary endpoints: 17 to 18 · 1 morev6 Show 4 more changesShow less
    • Primary endpoints revised (4)
    • Eligibility criteria expanded, about 228 words
    • Secondary endpoints: 17 to 18
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Site details revised at 2 of 5 sitesv5
  4. Site details revised at 1 of 5 sitesv4
  5. Site details revised at 1 of 5 sitesv3
  6. Start date changed from estimate of Jul 2023 to Jul 13, 2023v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cancer Research UK
15 trials monitored
See 2 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
and 9 more diseases
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.
Trial Details
NCT Number NCT05944237
Lead Sponsor Cancer Research UK
Collaborators: Nxera Pharma UK Limited
Conditions Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms +6 more
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov